Drug Profile
4T1/IL-2/GM-CSF vaccine - Theralink Technologies
Alternative Names: 4T1 whole cell vaccine - Theralink Technologies; 4T1-IL-2-GM-CSF-vaccine; OvcavaxLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator OncBioMune Pharmaceuticals
- Developer Theralink Technologies
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Ovarian cancer
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Injection)
- 28 May 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA (Intraperitoneal, Injection)
- 28 May 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA (SC, Injection)